Company
Immunic Inc
NASDAQ:IMUX
Immunic is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026.
107 stories · page 1 of 2
Immunic has a blockbuster clinical pipeline to treat multiple sclerosis and gastrointestinal diseases
The New York-based biotechnology company's promising lead asset vidofludimus calcium (IMU-838) is an oral drug in Phase 3 clinical trials for patients with multiple sclerosis